Sandbox: Difference between revisions

No edit summary
No edit summary
 
(441 intermediate revisions by 10 users not shown)
Line 1: Line 1:
{| class="wikitable"
{{#ask: [[Is DrugClass::Benzodiazepine]] | ?SeizureDose=Dose | ?BrandName=Trade Name}}
| align="center" style="background:#f0f0f0;"|'''Medication'''
 
| align="center" style="background:#f0f0f0;"|'''Dose'''
[[Scarlet_fever_1.2.jpg|thumb|"Slapped cheeks" and "white mustache" (circumoral pallor) typical of scarlet fever.]]
| align="center" style="background:#f0f0f0;"|'''Comments'''
 
| align="center" style="background:#f0f0f0;"|'''Contraindications'''
We heard you. '''Our native WikEM app is back!''' Download from your app store now ([http://apps.apple.com/us/app/wikem/id576405449 iOS] and [https://play.google.com/store/apps/details?id=wikem.chris Android]).
|-
 
| Calcium-Channel Blockers||||||
[http://mediawiki.org MediaWiki]
|-
 
| [[Diltiazem]]||
[http://apps.apple.com App]
*Bolus 0.25 mg/kg (average adult dose 20mg) over 2 min 
 
*If, after 15min 1st dose is tolerated but inadequate re-bolus 0.35 mg/kg 
[https://apps.apple.com App]
*If patient responds start infusion at 5-15mg/hr or give PO dilt 30mg QID
 
||
[http://apps.apple.com/us/app/wikem/id576405449 iOS]
*Preferred in patients with chronic lung such as [[Asthma]] and [[COPD]]<ref>Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011 May 10;342:d2549</ref>
 
||
[https://apps.apple.com/us/app/wikem/id576405449 https://play.google.com/store/apps/details?id=wikem.chris iOS]
*Decompensated heart failure
*Preexcitation (especially in pediatrics)  
*Significant hypotension
|-
| Beta-Blockers||||||
|-
| [[Metoprolol]]||
*Bolus 2.5-5mg IVP over 2min q5min up to 3 doses 
*If patient responds orally load with 25-50mg
||
*Particularly useful when A-fib a/w exercise, after acute MI, or w/ thyrotoxicosis 
*Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for acute conversion if they do not have any relative contraindications.<ref>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85</ref>
||
*COPD 
*Asthma 
*Decompensated heart failure 
*Hypotension
|-
| [[Esmolol]]||
*Bolus 0.5 mg/kg over one minute, followed by 50 µg/kg/min 
*If, after 4min response is inadequate, re-bolus followed by infusion of 100 µg/kg/min 
*If, after 4min response is still inadequate, try final bolus followed by infusion of 150 µg/kg/min 
*If necessary, infusion can be increased to maximum of 200 µg/kg/min after another four minutes
||
*Use if unsure whether patient will tolerate a beta blocker since the duration of action is only 10 minutes
||
|-
| Other||||||
|-
| [[Digoxin]]||||||
|-
|
||
*0.25 mg IV q2hr up to 1.5 mg, then 0.125-0.25 mg PO or IV QD 
*Adjust dose in presence of renal failure, amiodarone, etc
||
*Consider as initial therapy for pts with LV dysfunction who: 
**Do not achieve rate control targets on beta blockers alone 
**Cannot tolerate addition of or increased doses of beta blocker due to decompensated CHF 
**Would have digoxin added anyway to improve CHF symptoms independent of A-fib 
*Consider as initial therapy in pts with severe hypotension 
*Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate 
*May take up to 6-8 hours to work
||
|-
| [[Amiodarone]]||
*Load 3-7 mg/kg IV over 30 min; then 1200 mg over 24hr via continuous infusion or in divided oral dosesKhan IA et al. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. <ref>Int J Cardiol. 2003 Jun;89(2-3):239-48.</ref>
||
*Consider for patients with decompensated heart failure or those with accessory pathways 
*2nd-line agent for chronic rate control when BBs and CCBs, alone, combined, or when used with digoxin, are ineffective
||
|}

Latest revision as of 17:07, 8 April 2026